---
title: "Xinhua Pharmaceutical's OAB-14 dry suspension has completed enrollment of the first patient in… — post author — DecisionGateway"
description: "statement by post author, recorded 2026-11-11 — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1e68d-c517-7e25-961d-f3132f150ba2"
meta:
  "og:description": "statement by post author, recorded 2026-11-11 — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "Xinhua Pharmaceutical's OAB-14 dry suspension has completed enrollment of the first patient in… — post author — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statementSaid on 2026-11-11

# **Xinhua Pharmaceutical's OAB-14 dry suspension has completed enrollment of the first patient in China for Phase II clinical trials; Gaoguang Pharmaceutical's brain-penetrant TYK2/JAK1 inhibitor TLL-041 is positioned as a neurodegenerative disease candidate with global first-in-class potential.**

A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *新華製藥OAB-14乾混懸劑已完成Ⅱ期臨床中國首例患者入組；仍處IPO階段的高光製藥，其腦滲透性TYK2/JAK1抑制劑TLL-041被定位為具有全球首創潛力的神經退行性疾病候選藥物。*

stockintelligencenewsPublished 2026-11-11 [ Read source](https://t.me/stockintelligencenews/5715548)

## **Discussion**

## **Related claims**

[**LY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical trials in China and completed first dosing; LY03020, as the world's first TAAR1/5-HT2CR dual-target agonist, also lists psychotic disorders associated with Alzheimer's disease as a target indication.**post author · statement](https://dgw.tmarket.io/claims/01a1e68d-c4c4-7209-ba78-a0c0c258eb03) [**Simcere Pharmaceutical has partnered with Germany's Vivoryon to develop SIM0408 in China, targeting neurotoxic amyloid N3pE, and it has been approved by the CDE to enter clinical trials.**post author · statement](https://dgw.tmarket.io/claims/01a1e68d-c4ee-71c2-a8c8-2f67c0e9c71f) [**New Lotus, a supplier of traditional Chinese medicine decoction piece products, listed on its first day.**post text · statement](https://dgw.tmarket.io/claims/01a1e7eb-58d1-726a-8d5e-34073376fbda) [**The self-developed SHR-3201 injection has been approved by the National Medical Products Administration to conduct clinical trials, and it is intended for Alzheimer's disease.**post author · statement](https://dgw.tmarket.io/claims/01a1e68d-c4a1-70d6-b30d-574523915ce8) [**New Hehua, a supplier of traditional Chinese medicine decoction piece products, opened at HK$51.3 on its first trading day, nearly 28% above its IPO price.**香港電台 · statement](https://dgw.tmarket.io/claims/01a1e6c9-1434-752b-bfcb-8be2bbfed062) [**After acquiring a controlling stake in Green Valley Pharmaceutical, Fosun incorporated sodium oligomannate capsules, used for mild to moderate Alzheimer's disease, into its innovative drug pipeline and took over its post-marketing confirmatory clinical study.**post author · statement](https://dgw.tmarket.io/claims/01a1e68d-c502-7f47-9c8f-1735fd8c35ae)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts — every claim cited to its public source. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1e68d-c517-7e25-961d-f3132f150ba2#webpage","@type":"WebPage","description":"statement by post author, recorded 2026-11-11 — verbatim quote and source citation.","name":"Xinhua Pharmaceutical's OAB-14 dry suspension has completed enrollment of the first patient in… — post author — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1e68d-c517-7e25-961d-f3132f150ba2","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1e68d-c517-7e25-961d-f3132f150ba2#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1e68d-c517-7e25-961d-f3132f150ba2"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1e68d-c517-7e25-961d-f3132f150ba2#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"Xinhua Pharmaceutical's OAB-14 dry suspension has completed…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1e68d-c517-7e25-961d-f3132f150ba2#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-11","isBasedOn":"https://t.me/stockintelligencenews/5715548","text":"新華製藥OAB-14乾混懸劑已完成Ⅱ期臨床中國首例患者入組；仍處IPO階段的高光製藥，其腦滲透性TYK2/JAK1抑制劑TLL-041被定位為具有全球首創潛力的神經退行性疾病候選藥物。","url":"/claims/01a1e68d-c517-7e25-961d-f3132f150ba2"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
